Horizon Pharma plc Receives Health Canada Approval for RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid for the Treatment of Urea Cycle Disorders in Patients Two Years of Age and Older - Seite 3

About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets nine medicines through its orphan, primary care and specialty business units. Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the potential of RAVICTI to treat UCD patients, the periods of regulatory data and market protection attaching to the approval for RAVICTI in Canada, potential reimbursement and availability of RAVICTI in Canada and Horizon Pharma's strategy and plans to commercialize RAVICTI in Canada. These forward-looking statements are based on management expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include risks regarding whether Horizon Pharma will be able to obtain adequate pricing and reimbursement and successfully commercialize RAVICTI in Canada or elsewhere outside of the United States, whether physicians outside of the United States will prescribe RAVICTI, the availability and acceptance of competing products, whether Horizon Pharma is able to maintain regulatory data and market protections for RAVICTI in Canada, whether Horizon Pharma will be able to successfully execute its growth strategy outside of the United States, and other factors described in Horizon's filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings. Forward-looking statements speak only as of the date of this press release and Horizon does not undertake any obligation to update or revise these statements, except as may be required by law.

Contacts:
Investors:
John Thomas
Executive Vice President, Strategy and Investor Relations
[e-mail]

Tina Ventura
Vice President, Investor Relations
[e-mail]

U.S. Media Contact:
Geoff Curtis
Senior Vice President, Corporate Communications
[e-mail]

Ireland Media Contact:
Ray Gordon
Gordon MRM
[e-mail]